Drugs / Candiplus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03115073 | Apr 2017 → Jul 2018 | vulvovaginal candidiasis | ProFem GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candiplus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03115073 ↗ |
| Known as | ProF-001 | “This is a multi-center, randomized, prospective, active-controlled, double-blind, dose-escalation study comparing dose response of clinical efficacy, safety, local tolerability...” NCT03115073 ↗ |